VATS for Resection of Mediastinal Parathyroids

Sponsor
Hospital General Ajusco Medio (Other)
Overall Status
Completed
CT.gov ID
NCT05696405
Collaborator
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (Other)
4
168

Study Details

Study Description

Brief Summary

Background: hyperparathyroidism (HPT) is a disease caused by hypersecretion of one or more parathyroid glands, it can be associated with ectopic mediastinal parathyroid glands (MEPA) in 2% of cases. The use of video-assisted thoracoscopic surgery (VATS) for the surgical resection of these glands is a safe, cost-effective, and low-morbidity option for patients with MEPA. We report a case series of patients with this disease managed with VATS.

Patients & Methods: From 2008 to 2022, a retrospective study involving patients with MEPA and treated by VATS approach was performed in a tertiary hospital in Mexico City. Relevant biochemical and clinical variables such as imaging studies, pre and postoperative lab results, surgical strategy and outcomes, and pathological analyses were analyzed.

Condition or Disease Intervention/Treatment Phase
  • Procedure: VATS resection of MEPA

Detailed Description

Hyperparathyroidism (HPT) is a clinical disorder characterized by an inappropriately elevated paratohormone (PTH) due to hypersecretion of one or more parathyroid glands, that may develop secondary hypercalcemia and other metabolic disturbances. This disease includes various signs and symptoms such as nephrolithiasis, osteopenia and osteoporosis, depression, mental numbness, loss of appetite, nausea, vomiting, constipation among others. The abnormal secretion of PTH is most commonly caused by a single parathyroid gland adenoma in 85% of the cases, in the other 15% is due to multiple gland hyperplasia (15-20%)(1) or rarely from a parathyroid carcinoma (<1%). HPT occurs in both genders equally around the sixth decade(2). World HPT prevalence is estimated at 1 in every 500 women and 1 in every 2000 men(3).

Mediastinal ectopic parathyroid adenomas (MEPA) are rare tumors, constituting 1-2% of all parathyroid adenomas. These glands are inferior to the sternal notch and their location may vary from the superior mediastinum to the pericardium and diaphragm(4). The first report of a mediastinal parathyroid adenoma was in 1932 by Churchill in the patient Captain Charles E. Martell, who had 6 prior cervical explorations for his hyperparathyroidism until an ectopic gland was found in the superior mediastinum(5). Before the introduction of VATS, MEPA were usually resected by thoracotomy or a median sternotomy, currently with the daily use of minimally invasive surgery, VATS is being adopted as the procedure of choice.

The aim of this study to report a case series of patients with MEPA treated with VATS, along with a literature review.

Study Design

Study Type:
Observational
Actual Enrollment :
4 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Thoracoscopic Treatment of Mediastinal Ectopic Parathyroid Adenomas: A Case Series and Literature Review
Actual Study Start Date :
Jan 1, 2008
Actual Primary Completion Date :
Jan 1, 2022
Actual Study Completion Date :
Jan 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Biochemical cure of hyperparathyroidism [24hours]

    Normalization of Paratohormone leves

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with MEPA
Exclusion Criteria:
  • incomplete records

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Hospital General Ajusco Medio
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Karla VerĂ³nica Chavez-Tostado, MD, Hospital Reg. Lic. Adolfo Lopez Mateos
ClinicalTrials.gov Identifier:
NCT05696405
Other Study ID Numbers:
  • 004
First Posted:
Jan 25, 2023
Last Update Posted:
Jan 25, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Karla VerĂ³nica Chavez-Tostado, MD, Hospital Reg. Lic. Adolfo Lopez Mateos
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 25, 2023